Opportunities to go global are here!

Seeking PCSK9 small molecule inhibitor products, global rights, current stage不限.

Interested companies are invited to contact immediately: PharmaTimes BD Team

BD@drugtimes.cn

Case Study on Impurity Identification and Structural Analysis in Drug Development | Porton·PharmaTimes Live

Main Body: 1600 Words

Estimated reading time: 5 minutes

On January 27, 2026, Lisata Therapeutics announcedAlreadyWith Qilu PharmaceuticalMutually agree to terminate the "Exclusive License and Cooperation Agreement" signed by both parties in February 2021.

Screenshot source:Lisata Therapeutics, Inc. Official Website

The agreement originally authorized Qilu PharmaceuticalIn Greater China (including mainland China, Hong Kong, Macao, and Taiwan regions), exclusive development and commercialization of certepetide (formerly known asCEND-1) rights,All authorized rights have now been fully returned to Lisata Therapeutics.

This rights adjustment is not an isolated event; its context is clear and traceable.

One week ago (January 21), the private company announcedAcquisition of all outstanding common shares of Lisata Therapeutics, Inc. at $4.00 per share in cash.On this basis,Synchronously establish two contingent value rights (CVR) strongly associated with drug progress:

(1) If the rights to certepetide in Greater China revert to Lisata within 12 months after the closing, shareholders may receive $1.00 per share;

(2) When Kuva submits a New Drug Application (NDA) for the drug in any region or for any indication globally, an additional $1.00 per share will be awarded.

If both conditions are met,ShareholderTotal RecallReported premium can reach approximately180%. ThisForcertepetideThe rapid recovery of rights and interests provides a clear commercial motive, also reflecting the strategic importance the acquirer places on asset integrity.

KuvaItSo at any cost, the global rights to certepetide must be acquired."Completely taking it in is by no means a fleeting impulse."As early as November 2024, Kuva Labs had been authorized to use certepetide in its proprietary NanoMark™ platform technology to develop a new generation of magnetic resonance imaging agents for solid tumors.

Therefore, the essence of this full acquisition is that Kuva wants to create an integrated diagnosis and treatment platform.It can not only leverage certepetide's tumor targeting and penetration capabilities for more precise non-invasive tumor detection, but also fully control its global development and commercialization rights as a therapeutic drug, maximizing synergistic value.

The capital's bet is based on certepetideUnique Biological MechanismWith High Recognition of Clinical Potential.

Certepetide, as an internalized RGD (arginine-glycine-aspartic acid, Arg-Gly-Asp, iRGD) cyclic peptide analog,Cyclic structure containing 9 amino acids, with both tumor-specific targeting and penetration activity, as well as tumor microenvironment modulation properties.

Tumor Microenvironment Modulation Characteristics:certepetideCan modulate the tumor microenvironment, making tumors more sensitive to immunotherapy, including: selectively reducing TME immunosuppressive T cells and recruiting cytotoxic T cells.

Catalent's displayed xenotransplantation model data shows,Using the non-cytotoxic payload certepetide can enhance ADC efficacy and broaden the distribution of ADC cytotoxic payloads and antibodies within the tumor microenvironment.

October 8, 2025Catalent andLisata Therapeutics, Inc. reached a cooperation agreement, the former obtainedCertepetide integrates into its SMARTag® Antibody-Drug Conjugate (ADC) technology platform rights, jointly exploring the possibility of creating a new generation of targeted bioconjugate therapies.

Based on the aforementioned advantages, certepetide has demonstrated good safety and signals of enhancing the efficacy of standard therapies in multiple early clinical trials, andObtained in the United StatesFast Track Designation,Orphan Drug Designation for Pancreatic Cancer,Orphan Drug Designation for Glioma,Orphan Drug Designation for Osteosarcoma andOsteosarcoma Rare Pediatric Disease Designation,Has accumulated considerable policy access advantages.

Summary:

Despite the termination of authorization,Qilu Pharmaceutical andLisata Therapeutics, Inc.The cooperation has not been completely severed.

According to the announcement,Qilu Pharmaceutical has an obligation to continue and complete the Phase II clinical trial for metastatic pancreatic ductal adenocarcinoma that it has already initiated.。At the same time, Lisata Therapeutics, Inc. has also committed to negotiating with Qilu Pharmaceutical Co., Ltd. regarding the potential use of these trial data in the future.

This arrangement reflects industry standards, ensures the rights of research participants and the integrity of clinical data, and also preserves a data foundation for the potential future redevelopment of this drug in China.

References:

1.https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-enters-term-sheet-be-acquired-kuva-labs-400

2.https://ir.lisata.com/news-releases/news-release-details/lisata-therapeutics-announces-mutual-termination-license

3. Other Public Information

Cover Image/Abstract Image Source: Jimo AI

Merck's $30 Billion Acquisition Talks Stall!

2026-01-26

ConnexBio Knocks on the Door of the Hong Kong Stock Market, Joining the Global "Anti-Aging" Science Race

2026-01-26

First in China! AstraZeneca's "Eculizumab" New Indication Approved in China

2026-01-26